Rivanna’s handheld ultrasound device Accuro receives FDA clearance

Accuro™ provides untethered ultrasound imaging to automatically guide spinal anesthesia with additional indications for ultrasound imaging of abdominal, musculoskeletal, cardiac, and peripheral vascular anatomies

Rivanna Medical announced today that it has received FDA 510(k) clearance to market Accuro™, a handheld and untethered smart phone-sized ultrasound device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies.

The Accuro™ platform is designed to provide automated navigation to an anatomical target so a clinician may avoid “guessing” where the target is. The initial commercial application of RIVANNA’s Accuro™ platform is designed for guiding clinicians to a first-attempt success in administering spinal anesthesia.

“There are multiple clinical uses for Accuro™, a disruptive, game-changing device platform technology,” said John A. Williams, President and CEO. “The Accuro™ platform, which is based on automated superior imaging technology, has an addressable $1+ billion U.S. market today. Because of the considerable unmet clinical need for automated image guidance in general, and in the spinal anesthesia market especially, we are looking forward to launching Accuro™ at the upcoming annual scientific meeting of the American Society of Anesthesiologist (ASA) in San Diego in just three months.”